Back to Journals » Drug, Healthcare and Patient Safety » Volume 3

Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease

Authors David N Roberts, Philip B Miner

Published 3 March 2011 Volume 2011:3 Pages 1—8

DOI https://doi.org/10.2147/DHPS.S7329

Review by Single-blind

Peer reviewer comments 3

David N Roberts1, Philip B Miner2
1Department of Internal Medicine, Digestive Diseases Section, University of Oklahoma, 2Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, USA

Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for reduction of pain and inflammation, particularly in the setting of rheumatologic disorders. While effective, they are associated with risks, including nephrotoxicity, gastrointestinal inflammation, peptic ulcer disease, and worsened cardiovascular outcomes. After development of cyclo-oxygenase 2 inhibitors to minimize gastrointestinal complications, early use revealed increased cardiovascular event rate risk, and retrospective analysis of traditional NSAIDs revealed similar concerns, with the exception of naproxen. PN400 is a fixed-dose combination formulation designed to provide sequential delivery of a nonenteric-coated, immediate-release esomeprazole 20 mg mantle followed by an enteric-coated naproxen 500 mg core. This review summarizes the pharmacokinetics, benefits, safety, and tolerability of PN400. Phase I trials demonstrated pharmacokinetics consistent with its formulation, and at different esomeprazole combination doses, PN400 containing esomeprazole 20 mg was the lowest dose that still resulted in substantial sustained increases of gastric pH > 4. In two Phase III trials (Study 301 and Study 302), PN400 resulted in a significant reduction in gastric ulcers relative to enteric-coated naproxen (4.1% to 23.1% in Study 301, 7.1% to 24.3% in Study 302). Discontinuation due to NSAID-associated upper gastrointestinal adverse events or duodenal ulcers was significantly less in PN400 patients (3.2% to 12%, P < 0.001, in Study 301; 4.8% to 11.9%, P = 0.009, in Study 302). Two subjective patient indices were utilized to assess tolerability, ie, the Severity of Dyspepsia Assessment (SODA) and Overall Treatment Evaluation of Dyspepsia (OTE-DP). Patients with PN400 had significantly better upper gastrointestinal tolerability compared with those treated with enteric-coated naproxen in terms of SODA scores, proportion of heartburn-free patients, and OTE-DP response. While no formal recommendations are available at this time for use of this new combination medication, it will likely become an important treatment option with application for many patients.

Keywords: esomeprazole, naproxen, combination, gastrointestinal tolerability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper

de Araújo AN, do Nascimento MA, de Sena EP, Baptista AF

Drug, Healthcare and Patient Safety 2014, 6:21-27

Published Date: 10 March 2014

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin

Jeske W, Walenga JM, Hoppensteadt D, Fareed J

Drug, Healthcare and Patient Safety 2013, 5:133-141

Published Date: 10 June 2013

Analysis of indoor air pollutants checklist using environmetric technique for health risk assessment of sick building complaint in nonindustrial workplace

Syazwan AI, Mohd Rafee B, Juahir H, Azman AZ, Nizar AM, Izwyn Z, Syahidatussyakirah K, Muhaimin AA, Syafiq Yunos MA, Anita AR, Muhamad Hanafiah J, Shaharuddin MS, Mohd Ibthisham A, Mohd Hasmadi I, Mohamad Azhar MN, Azizan HS, Zulfadhli I, Othman J, Rozalini M, Kamarul FT

Drug, Healthcare and Patient Safety 2012, 4:107-126

Published Date: 21 September 2012

An exploratory study on medications in Qatar homes

Kheir N, El Hajj MS, Wilbur K, Kaissi RML, Yousif A

Drug, Healthcare and Patient Safety 2011, 3:99-106

Published Date: 20 December 2011